Kenneth J. Russell, M.D.

 

Associate Professor,
Radiation Oncology
University of Washington Medical Center
Department of Radiation Oncology,
University Cancer Center
University of Washington Medical Center

Medical Director, Radiation Oncology
Seattle Cancer Care Alliance

Dr. Ken Russell specializes in prostate cancer, prostate brachytherapy, lymphoma and total body irradiation.

Dr. Russell decided to become a doctor because he wanted to take care of sick people who needed help. His guiding philosophy for patient care is to advise his patients as he would his own family members.

When Dr. Russell isn’t practicing medicine he is busy raising his two teenagers.

CURRICULUM VITAE

Education:

1971-1975 Harvard College, Cambridge, Massachusetts
BA, Biology (magna cum laude)
1975-1979 Harvard Medical School, Boston, Massachusetts
M.D.

Postgraduate Training:

1980-1983 Resident, Radiation Therapy Division, Stanford University Hospital, Stanford, California.

7/82-10/82 Chief Resident, Radiation Therapy Division, Stanford University Hospital, Stanford, California.

 

7/83-6/84 American Cancer Society Post-Doctoral Fellow, Division of Radiobiology, Stanford University Hospital, Stanford, California.

7/84-6/85 Post-Doctoral Fellow, Program in Cancer Biology, Division of Radiobiology, Stanford University Hospital, Stanford, California

1998 Program for Chiefs of Clinical Services, Harvard School of Public Health

Professional Licensure:

1980-present State of California

1985-present State of Washington

Board Certification:

1979 Diplomate, National Board of Medical Examiners

1984 Therapeutic Radiology, American Board of Radiology

Faculty Appointments:

1990-2001 Associate Professor, Department of Radiation Oncology,
University of Washington, Seattle, Washington.

1997 Acting Chairman, Department of Radiation Oncology,
Seattle Veteran’s Administration Hospital, University of Washington, Seattle, Washington.

1999-present Affiliate Investigator, Division of Clinical Research,
Fred Hutchinson Cancer Research Center, Seattle, Washington.

1999-2001 Medical Director, Total Body Irradiation Facility,
Fred Hutchinson Cancer Research Center, Seattle, Washington.

2001-present Professor, Department of Radiation Oncology,
University of Washington, Seattle, Washington.

 

2001-present Medical Director, Radiation Oncology
Seattle Cancer Care Alliance, Seattle, Washington

Honors:

1975 Phi Beta Kappa, Harvard College.
1983 Robert Reid Newell Memorial Award (Outstanding Resident), Department of Radiology, Stanford University School of Medicine.
1996-present “Seattle’s Best Doctors”, Seattle Magazine.

Professional Organizations:

1983-present American Society for Therapeutic Radiology and Oncology
1984-1989 American Medical Association
1988-present American Radium Society
1988-present American Society of Clinical Oncology
1988-present Radiation Research Society
1991-1993 American Cancer Society, Seattle Division.
1994-present Radiological Society of North America
1996-1998 American College of Radiation Oncology
1997-present King County Medical Society
1988-1990 Program Director, Washington State Radiological Society, Division of Radiation Oncology
1990-1992 Treasurer, Washington State Radiological Society, Division of Radiation Oncology
1992-1994 President, Washington State Radiological Society, Division of Radiation Oncology

Local Responsibilities:

1985-1990 Member, UWMC Tumor Board.
1985-present Member, Puget Sound Oncology Consortium (PSOC) Genitourinary Cancer Committee.
1985-1993 Member, Seattle Veteran’s Affairs Medical Center Tumor Board.

 

1985-present Member, University of Washington Lymphoma/Leukemia Tumor Board.
1995-present Member, University of Washington Genitourinary Tumor Board
1997-1998 Consultant to Fred Hutchinson Cancer Research Center Total Body Irradiation (TBI) Facility
1999-2001 Medical Director, Fred Hutchinson Cancer Research Center Total Body Irradiation Facility
1999-present Affiliate Investigator, Division of Clinical Research, Fred Hutchinson Cancer Center

University of Washington Medical Center – Administrative

1985-1991 Member, University of Washington Medical School Administrative Committee.
1988 Member, University of Washington School of Medicine Surgical Oncology Review Committee.
1989 Member, University of Washington School of Medicine Surgical Oncology Search Committee.
1989 Member, University of Washington School of Medicine University of Washington Physicians Nominating Committee for Trustees at Large.

1992-1994 Representative to University of Washington Faculty Senate
1997-2001 Member, Joint Oncology Patient Care Committee, University of Washington Medical Center – Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance (SCCA)

1998-2001 Chair, Radiation Oncology Working Group, SCCA
1999-2001 Member, Adult Operations Team, SCCA
1999-2001 Member, Multidisciplinary Care working group, Physician Practice Plan Subcommittee, SCCA

1998-2000 Member, University of Washington School of Medicine Radiation Safety Committee
1998 Selection Committee, SCCA Medical Director recruitment.

1999-2001 Member, Management Guidance Team, SCCA
2000-2001 Member, Clinic Operations Team (COT), SCCA
2001-present Member, General Oncology Clinic Operations Team, SCCA

University of Washington Medical Center – Educational

1987-1993 Member, UWMC-American Cancer Society Institutional Grant Review Committee.
1991-present Medical Student Career Advisor, UWMC.
1992-1993 Medical Student “Vertical” Advisor UWMC
University of Washington Medical Center – Teaching

Courses:

1985 – present Faculty instructor, UWMC Radiation Oncology clerkship RadOnc #695
1985 – present Annual Department Clinical Radiation Oncology Lecture Series – Annual lectures on malignancies of prostate, bladder, esophagus, and colorectum, Hodgkin’s disease and non-Hodgkin’s lymphomas.

1989 Faculty Supervisor, Independent Study in Medical Science (ISMS) Program, UWMC – Christopher Dunatov – PSA following primary radiation of prostate cancer

1996 Faculty Supervisor, ISMS Program, UWMC – Monica Vuong – Neutron radiation of recurrent prostate cancer

Lectures-Local:

1. Diffusion-Limited Chemotherapy for Radiation Potentiation. Department of Radiation Oncology “R.O.C.” series, University of Washington, 4/7/86.

2. Matrix-Associated Chemotherapy. Grand Rounds, Departments of Hematology and Oncology, University of Washington, 3/9/86

3. New Approaches in the Treatment of Bladder Cancer. Grand Rounds, Departments of Hematology and Oncology, University of Washington, 6/2/86.

4. Principles of Radiation Therapy. Medical Oncology Board Review Course, University of Washington, 1987-1991.

5. Current Status of Fast Neutron Therapy for Solid Tumors. Hematology/Oncology Grand Rounds, University of Washington, Seattle, Washington, 3/11/89.

6. Can we use Radiobiological Principles in the Design of Clinical Trials? Northwest Radiobiology Review Course. University of Washington, Seattle, Washington, 4/26/91.

7. Radiation Therapy and the Treatment of Dermatologic Malignancy. Dermatology Boards Review Course, University of Washington, Seattle, Washington, 1995, 1996.

8. Conformal Radiotherapy for Locally Advanced Prostatic Cancer. Grand Rounds, Department of Urology, University of Washington Medical Center, 9/23/92.

9. Radiation Therapy in the Management of Localized Prostatic Cancer. Resident Lecture Series, Department of Urology, University of Washington Medical Center, 5/19/92.

10. Radiation Therapy of the Skin. University of Washington Department of Dermatology, Resident Conference, Seattle, Washington, 1995, 1996, 1997, 1998.

11. Radiation Therapy of Prostate Cancer. University Cancer Center Prostate Cancer Patient Support Group – 1995, 1996, 1997, 1998, 1999

Continuing Medical Education – Local:

1. Advances in the Radiotherapeutic Management of Urologic Malignancy. University of Washington and American Cancer Society Course of Continuing Medical Education, Management of Urologic Cancer in the 80′s, Seattle, Washington, 6/21/86.

2. Intraoperative Irradiation. University of Washington Course of Continuing Medical Education, Missouri Chapter of American College of Surgery, 5/1/87.

3. Preliminary Results of PSOC #613: 5-Fluorouracil and Irradiation in the Treatment of Bladder Cancer. Puget Sound Oncology Consortium Quarterly Meeting, Swedish Hospital, Seattle, Washington, 10/16/87.

4. Cancer Treatment: The Prostate Debate: Radiation Oncology. American Cancer Society Forum, Cancer Research: Where are We? A Forum for Members of the News Media. University of Washington, 4/1/88.

5. Radiotherapeutic Management of Bladder Cancer: Past Perspectives, Current Trials, and Future Directions. Washington State Radiological Society, Division of Radiation Oncology, Seattle, Washington, 5/13/88.

6. Update in Therapeutic Modalities – Radiotherapy. University of Washington Course of Continuing Medical Education, General Oncology Update for Physicians and Nurses, Seattle, Washington, 4/28/88.

7. New Developments in the Treatment of Locally Advanced Prostate Cancer. University of Washington CME Course: Recent Advances in Cancer Detection and Treatment, Seattle, Washington, 3/90.

8. PSA Following Primary External Beam Treatment of Prostate Adenocarcinoma. Pacific Northwest Cancer Foundation Course: Prostate Cancer – The Role of Interstitial Implantation: An Update of Recent Data, Seattle, Washington, 6/26/92.

9. PSA Following Primary External Beam Treatment of Prostate Adenocarcinoma. Pacific Northwest Cancer Foundation Course: Prostate Cancer – The Role of Interstitial Implantation, Seattle, Washington, 6/21/93.

10. Current Status of PSA Following Primary External Beam Treatment of Prostate Adenocarcinoma. Pacific Northwest Cancer Foundation Course: Prostate Cancer – The Role of Interstitial Implantation, Seattle, Washington, 6/23/94.

11. Prostate Cancer: The Radiotherapy Approach. University of Washington Prostate Cancer Symposium, Seattle, Washington, 10/14/94.

12. Research Directions in the Radiotherapy for Prostate Cancer. University of Washington Prostate Cancer Symposium, Seattle, Washington, 10/14/94.

13. Outcomes of External Beam Radiation. Pacific Northwest Cancer Foundation Course: Prostate Cancer – Transperineal Brachytherapy for Early Stage Prostate Cancer: Into the Mainstream, Seattle, Washington, 6/22/95.

14. Transperineal Radioactive Seed Implantation. University of Washington Continuing Medical Education. 3/97, 4/97, 5/97.

Clinical Trials – Local

Study Chairman, Puget Sound Oncology Consortium Study #613, Primary Megavoltage Irradiation and Chemotherapy as Alternative to Cystectomy in Bladder Cancer Patients Who Achieve Complete Regression of Tumor with Preoperative Irradiation and 5-Fluorouracil.

Principal Investigator, Puget Sound Oncology Consortium Study #702, Aggressive Multimodality Management of Adenocarcinoma of the Exocrine Pancreas.

Principal Investigator, UW #86-03 Technetium 99m Galactosyl-Neoglycoalbumin Imaging of the Human Liver: A New Approach to Understanding Radiation Injury of the Liver.

Principal Investigator, UW #85-03 Phase I/II Evaluation of Continuous Infusion 5-Fluorouracil as a Potentiator of Intracavitary Brachytherapy in the Treatment of Expansive Endocervical Cancer of the Uterine Cervix, FIGO Stages Ib and IIa.

Principal Investigator, UW #85-02 Diffusion Limited Chemotherapy for Recurrent or Metastatic Cancer: Pilot Study of an Injectable Colloidal Drug Suspension.

Principal Investigator: UW #91-00 Cytotoxic Chemotherapy Followed by Androgen Ablation for Patients with Subclinical Recurrence of Prostate Cancer Following Primary Radiation Therapy.

Radiotherapy Coordinator: UWMC #93-01 Phase II Study of Pre-operative Chemoradiation with Hepatic Irradiation and Electron Beam Intraoperative Radiotherapy for Non-metastatic Resectable Adenocarcinoma of the Pancreas.

Principal Investigator: UW #27-0507-B (1998): Use of post-operative radiographs to identify the anatomic location of surgical margins following radical prostatectomy for prostatic cancer.
Investigator: UWMC/SVAH trial: I-125 versus Palladium-103 for low risk prostate cancer (1998 – 2002).

Investigator, FHCRC/UWMC #1164.00 – Pilot Study of High-Dose Immunoablative Therapy using Total Body Irradiation Anti-Thymocyte Globulin and Cyclophosphamide followed by Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation for Patients with Multiple Sclerosis (1999).

Investigator, FHCRC/UWMC #1019.01 – A Pilot Study of High-Dose Immuoablative Therapy using Total Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphaide followed by Autologous Transplantation with DC34 Selected Peripheral Blood Stem Cells for Patients with Systemic Sclerosis (1999).

Investigator, FHCRC/UWMC #160.06 – Treatment of Patients with Hematological Malignancies using Marrow Transplantation from NLA Matched Unrelated Donors (2000).

Investigator, FHCRC/UWMC #1467.00 – Treatment of Patients with Hematological malignancies using Marrow Transplantation from Unrelated Donors Incompatible for one HLA Locus Antigen (2000).

Editorial Responsibilities:

Manuscript Reviewer:

Journal of Clinical Oncology
Cancer
International Journal of Radiation Oncology, Biology, and Physics
International Journal of Radiation Biology
Journal of the American Medical Association (JAMA)
Radiation and Environmental Physics

Residency Education

1991 Examiner, Oral Board Examination, American Board of Radiology Specialty Board Certification: Lymphoreticular Neoplasms

1994- 1996 Residency Program Site Reviewer, Accreditation Council for Graduate Medical Education.)

 

1992-1999 Examiner, Oral Board Examination, American Board of Radiology Specialty Board Certification: Genitourinary Neoplasms – 1992, 1996, 1997, 1999

National Cooperative/Research Groups

1985-1991 Member, Radiation Therapy Oncology Group Genitourinary Committee.

1986-present Member, Southwest Oncology Group Genitourinary Committee.

1986-present Disease Site Designate – Bladder Cancer – Southwest Oncology Group Genitourinary Committee.

1986-present Member, Southwest Oncology Group Normal Tissue Tolerance Committee.

1994 Member, 1994 United States “Patterns of Care Study” Prostate Cancer Consensus Committee

1994 Member, 1994 United States “Patterns of Care Study” Testicular Cancer Consensus Committee

1998 Member, Panel of Prostate Cancer Experts, United States Study of “Prostate Cancer Quality of Care”, RAND Corporation.

1999 Member, Prostate Cancer Trialists’ Collaborative Group (PCTCG)

2000 Grant Reviewer, Grants Review Branch, National Cancer Institute, Special Emphasis Panel, “Quick Trials for Prostate Cancer Therapy”

National Scientific Organizations:

American Society of Therapeutic Radiology and Oncology (ASTRO):

1995-present Scientific Abstract Reviewer
1995-present Annual Meeting Session Moderator – Prostate (1995), Genitourinary Cancer (1996, 1997), Prostate (1998)

1996-present Member, Scientific Program Committee
1996-present Invited Faculty, “Meet the Professor” Faculty Program
1997 Member, Publications Committee1998 Member, Resident Clinical/Basic Research Committee
1997-2000 Nationally Elected Member, ASTRO Officer Nominating Committee
1999, 2000 Moderator, Plenary Session, Annual Meeting
1998-2001 Chairman, Scientific Program, Annual Meeting and Program Committee

2001-2004 Elected Member, Board of Directors, Academic Member-at-Large

American Radium Society (ARS)

1996-present Member, Scientific Program Committee
1996-1998 Scientific Abstract Reviewer
1997- present Session Moderator – Advanced Technology Symposium (1997), Prostate Brachytherapy (1998), Genitourinary Cancer (1999), Prostate Cancer (2001)
1998 Chairman, Scientific Program Committe Radiological Society of North America (RSNA)
1998-present Member, Scientific Program Committee
1999 Scientific Abstract Reviewer

Clinical Trials Leadership:

Study Chairman, Radiation Therapy Oncology Group #85-23: Randomized Study to Compare Fast Neutron Irradiation versus Photon Irradiation for Stages B2, C, and D1 Adenocarcinoma of the Prostate Gland.

Study Chairman, Southwest Oncology Group #87-33: Evaluation of Operable Bladder Cancer Patients with Pre-operative Irradiation Plus 5?FU and Inoperable Patients with Irradiation Plus 5-FU Alone,
Phase II.

Radiotherapy Study Chairman, Radiation Therapy Oncology Group #1051: Radical Prostatectomy versus Radiation Therapy for Adenocarcinoma of the Prostate with DNA Flow Cytometric Analysis (Stages TA, TB, N0, M0), Phase III: An Intergroup Study.

Radiotherapy Study Chairman, Lung Cancer Study Group: A Prospective Randomized Study of Post-Operative Adjuvant Radiation and Chemotherapy in Resected Stages IIB and III Adenocarcinoma of the Esophagus.

Radiotherapy Study Coordinator, Southwest Oncology Group #93-06: Intergroup Study of Conservative Treatment of Adenocarcinoma of the Distal Rectum – Local Excision Plus Adjuvant Radiation and Concurrent 5-FU in Selected Patients.

UWMC Principal Investigator, RTOG #94-06 – A Phase I/II Dose Escalating Study Using Three Dimensional Conformal Radiation Therapy for Adenocarcinoma of the Prostate.
Radiotherapy Co-Chair. American College of Surgeons Oncology Group (ACOSOG) Study #Z0070 – Radical Prostatectomy versus Prostate Brachytherapy for Localized Adenocarcinoma of the Prostate (2000).

Radiotherapy Co-Chair. American College of Surgeons Oncology Group (ACOSOG) Study #Z0071 – Quality of Life Outcomes for patients treated with Radical Prostatectomy versus Prostate Brachytherapy for Localized Adenocarcenoma of the Prostate on Protocol Z0070. (2000)

Research Funding:

1987 American Society for Therapeutic Radiology and Oncology Research and Travel Fellowship.

1987-1989 Clinical Oncology Career Development Award, American Cancer Society, Inc. $105,000

1988-1989 University of Washington Biomedical Research Support Grant.

1992-1995 1RO1 CA58954-01 Isolation of human genes that confer radiation resistance. MT Groudine, Principal Investigator, KJ Russell, Co?Investigator, 10/1/92-10/1/95. National Institutes of Health. Total cost $807,399.

1998-1999 P53 and tumor response to radiotherapy. Royalty Research Fund, University of Washington. JL Schwartz, Principal Investigator, KJ Russell, Co-Investigator.

 

Bibliography

Peer Reviewed (* = Invited):

1. Russell KJ, Donaldson SS, Cox RS, Kaplan HS: Childhood Hodgkin’s Disease: patterns of relapse. Journal of Clinical Oncology 2(2): 80-87, 1984.

2. Russell KJ, Hoppe RT, Colby TV, Burns BF, Cox RS, Kaplan HS: Lymphocyte predominant Hodgkin’s Disease: clinical presentation and results of treatment. Radiotherapy and Oncology 1(3): 197-205, 1984.

3. Russell KJ, Rice GC, Brown JM: In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine. Cancer Research 46(6): 2883?2887, 1986.

4. Russell AH, Burt AR, Ek M, Russell KJ, Cain JM, Greer BE, Tamimi HK, Figge DC: Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence. Gynecologic Oncology 28(2): 220-224, 1987.

5. Russell AH, Jones DC, Russell KJ, Gerdes AJ, Figge DC, Greer BE, Tamimi HK, Cain JM: High dose para-aortic lymph node irradiation for gynecologic cancer: technique, toxicity, and results. Int. J. Radiat. Oncol. Biol. Phys. 13(2): 267-271, 1987.

6. Russell AH, Koh W-J, Markette K, Russell KJ, Cain JM, Tamimi HK, Greer BE, Figge DC: Radical re-irradiation for recurrent or second primary carcinoma of the female reproductive tract. Gynecologic Oncology 27(2): 226-232, 1987.

7. Russell KJ, Laramore GE, Krall JM, Thomas FJ, Maor MH, Hendrickson FR, Krieger JN, Griffin TW: Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer: updated results of the RTOG 7704 randomized clinical trial. Prostate 11(2): 183-193, 1987.

8. Griffin BR, Laramore GE, Russell KJ, Griffin TW, Eenmaa J: Fast neutron radiotherapy for advanced malignant salivary gland tumors. Radiotherapy and Oncology 12(2): 105-111, 1988.

9. Griffin BR, Livingston RB, Stewart GR, Higano C, Russell KJ, Griffin TW, Laramore GE: Prophylactic cranial irradiation for limited non-small cell lung cancer. Cancer 62(1): 36-39, 1988.

10. Russell KJ, Boileau MA, Ireton R, Higano CS, Collins C, Koh W-J, Griffin BR, Chapman WH, Griffin TW: Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 167(3): 845-848, 1988.

11. Griffin BR, Eskridge JM, Glover NT, Berger MS, Russell KJ, Shuman WP: Improved radiotherapy treatment planning for spinal cord tumors using gadolinium enhanced magnetic resonance imaging. Medical Dosimetry 14(1): 5-8, 1989.

12. Koh W-J, Laramore G, Griffin T, Russell K, Griffin B, Parker R, Davis L, Pajak T: Fast neutron radiation for inoperable and recurrent salivary gland cancers. American Journal of Clinical Oncology 12(4): 316-319, 1989.

13. Krieger JN, Krall JM, Laramore GE, Russell KJ, Thomas FS, Maor MH, Hendrickson FR, Griffin TW: Fast neutron radiotherapy for locally advanced prostate cancer. Update of a past trial and future research directions. Journal of Urology 34(1): 1-9, 1989.

14. Laramore GE, Griffeth JT, Boespflug M, Pelton JG, Griffin TW, Griffin BR, Russell KJ, Koh W-J, Parker RG, Davis LW: Fast neutron radiotherapy for sarcomas of soft tissue, bone and cartilage. American Journal of Clinical Oncology 12(4): 320-326, 1989.

15. Russell KJ, Boileau MA, Ireton RC, Higano CS, Collins C, Koh W-J, Griffin BR, Chapman WH, Griffin TW: Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Urology/Nephrology Digest 2: 25-26, 1989.

16. Russell KJ, Hoppe RT: Response of mediastinal Hodgkin’s disease to radiotherapy: rate of tumor regression not predictive of outcome. Int. J. Radiat. Oncol. Biol. Phys. 16(1): 201-204, 1989.

17. Russell KJ, Koh W-J, Russell AH, Griffin BR, Markette KL, Tong DY, Griffin TW: Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy. Journal of Urology 141(1): 30-32, 1989.

18. Russell KJ, Laramore GE, Griffin TW, Parker RG, Davis LW, Krall JM: Fast neutron radiotherapy for the treatment of carcinoma of the urinary bladder. A review of clinical trials. American Journal of Clinical Oncology 12(4): 301-306, 1989.

19. Russell KJ, Laramore GE, Griffin TW, Parker RG, Maor MH, Davis LW, Krall JM: Fast neutron radiotherapy in the treatment of locally advanced adenocarcinoma of the prostate. Clinical experiences and future directions. American Journal of Clinical Oncology 12(4): 307-310, 1989.

20. Stewart G, Griffin TW, Griffin BR, Laramore G, Russell KJ, Parker RG, Maor MN, Davis LW: Neutron radiation therapy for unresectable non-small cell carcinoma of the lung. A review. American Journal of Clinical Oncology 12(4): 290-294, 1989.

21. Wells G, Koh W-J, Pelton J, Russell K, Griffin B, Laramore G, Griffin T, Parker R, Peters LJ, Davis L, Pajak TF: Fast neutron teletherapy in advanced epidermoid head and neck cancer. A review. American Journal of Clinical Oncology 12(4): 295-300, 1989.

22. Koh W-J, Austin-Seymour MM, Russell KJ, Griffin BR, Laramore GE, Griffin TW: Current use of electron beam therapy in the United States. La Radiologia Medica 80: (4 Suppl 1): 26-27, 1990.

23. Koh W-J, Russell KJ, Cain JM, Greer BE, Tamimi HK, Figge DC, Laramore GE, Griffin TW: Intraoperative electron beam therapy. La Radiologia Medica 80: (4 Suppl 1): 86-87, 1990.

24. Leibel SA, Guse C, Order SE, Hendrickson FR, Komaki RU, Chang CH, Brady LW, Wasserman TH, Russell KJ Asbell SO, Phillips TL, Russell AH, Pajak TF: Accelerated fractionation radiation therapy for liver metastases: selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. Int. J. Radiat. Oncol. Biol. Phys. 18(3): 523?528, 1990.

25. Russell KJ, Boileau MA, Higano C, Collins C, Russell AH, Koh W-J, Cole SB, Chapman WH, Griffin TW: Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int. J. Radiat. Oncol. Biol. Phys. 19(3): 693-699, 1990.

26. Russell KJ, Laramore GE, Krieger JN, Wiens LW, Griffeth JT, Koh W-J, Griffin BR, Austin?Seymour MM, Griffin TW, Davis LW: Transient and chronic neurological complications of fast neutron radiation for adenocarcinoma of the prostate. Radiotherapy and Oncology 18(3): 257-265, 1990.

*27. Russell KJ, Dunatov C, Hafermann MD, Griffeth JT, Polissar L, Pelton J, Cole SB, Taylor EW, Wiens LW, Koh W-J, Austin-Seymour MM, Griffin BR, Russell AH, Laramore GE, Griffin TW: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. Journal of Urology 146(4): 1046-1052, 1991.

28. Koh W-J, Chiu M, Stelzer KJ, Greer BE, Mastras DG, Comsia N, Russell KJ, Griffin TW: Femoral vessel depth and the implications for node radiation. Int. J. Radiat. Oncol. Biol. Phys. 27: 969-974, 1993.

29. Koh W-J, Wallace HJ, Greer BE, Cain J, Stelzer KJ, Russell KJ, Tamimi HK, Figge DC, Russell AH, Griffin TW: Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Int. J. Radiat. Oncol. Biol. Phys. 26: 809-816, 1993.

30. Laramore GE, Krall JM, Thomas FJ, Russell KJ, Maor MH, Hendrickson FR, Martz KL, Griffin TW, Davis LW: Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. American Journal of Clinical Oncology 16(2): 164-167, 1993.

31. Austin-Seymour M, Caplan R, Russell K, Laramore G, Jacky J, et al: Impact of a multileaf collimator on treatment morbidity in localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 30(5):1065-1071, 1994.

32. Koh W-J, Griffin TW, Laramore GE, Stelzer KJ, Russell KJ. Fast neutron radiation therapy: results of phase III randomized trials in head and neck, lung and prostate cancers. Acta Oncologica, 33(3): 293-298, 1994.

*33. Russell KJ, Caplan RJ, Laramore GE, Burneson CM, Maor MH, Taylor ME, Zink S, Davis LW, Griffin TW: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 28: 47-54, 1994.

34. Stelzer KJ, Hibbert K, Koh W-J, Russell KJ, Griffin TW. Association between methylxanthine consumption and a lower incidence of severe chronic radiation toxicity in patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 30, Suppl 1:237, 1994.
35. Stelzer KJ, Laramore GE, Griffin TG, Koh W-J, Austin-Seymour M, Russell KJ, Buchholz TA: Fast neutron radiotherapy: the University of Washington Experience. Acta Oncologica, 33(3):275-280, 1994.

36. Koh W-J, Stelzer KJ, Peterson LM, Staker BL, Ward WF, Russell KJ, Griffin TW: Effect of pentoxifylline on radiation-induced lung and skin toxicity in rats. Int. J. Radiat. Oncol. Biol. Phys., 31(1):71-77, 1995.

*37. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, Groudine M: Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient G1 checkpoint-competent cells. Cancer Research, 55:1639-1642, 1995.

38. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and Flutamide for prostate cancer, a pilot study. Urology 48(5):800-804, 1996.

39. Lindsley KL, Cho P, Stelzer KJ, Koh W-J, Austin-Seymour M, Russell KJ, Laramore GE, Griffin TW. Clinical trials of neutron radiotherapy in the United States. Bull Cancer/Radiother 83(1):78s-86s, 1996.

*40. Russell KJ, Wiens LW, Demers GW, Galloway DA, Le T, Rice GC, Bianco JA, Singer JW, Groudine M. Preferential Radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int. J. Radiat. Oncol. Biol. Phys. 36(5):1099-1106, 1996.

41. Raymond JF, Vuong BS, Russell KJ: Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int. J. Radiat. Biol. Phys. 41 (1): 93-99 1998.

42. Bellon J, Wallner K, Ellis W, Russell K, Cavanaugh W, Blasko J. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 43(3): 579-581, 1999.

43. Wallner K, Ellis W, Russell K, Cavanaugh W, Blasko J. Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 43(3), 583-585, 1999.

44. Schwartz JL, Rasey J, Wiens L, Jordan R, Russell KJ: Functional inactivation of p53 by HPV-E6 transformation is associated with a reduced expression of radiation-induced potentially lethal damage, Int. J. Radiat. Biol.75(3), 285-91, 1999.

*45. Schwartz JL, Russell KJ: The effect of functional inactivation of p53 by HPV-E6 transformation on the induction of chromosome aberrations by gamma rays in human tumor cell. Radiation Research 151 (4), 385-90, 1999.

46. Michalski JM, Purdy JA, Winter K, Roach, M III, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, and Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int. J. Radiation Oncology Biol. Phys., 46(2): 391-402, 2000.

47. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trial. Lancet, Vol 355, #9214, 4/29/00, pp. 1491-1498.

48. Schwartz JL, Jordan R, Kaufmann WK, Rasey J, Russell KJ, Weichselbaum RR. Evidence for the expression of radiation-induced potentially lethal damage being a p53-dependent process. Int. J. Radiation Biol., 76 (8) 1037-1043, 2000.

Non-Peer Reviewed (Invited)

1. Meselson M, Russell KJ: Comparisons of carcinogenic and mutagenic potency. In: Origins of Human Cancer, Cold Spring Harbor Laboratory, 1977: 1473-1481.

2. Boileau MA, Russell KJ: Invasive bladder cancer. Strategies for cure and bladder preservation. Hematology/Oncology Clinics of North America 2(3): 447-455, 1988.

3. Griffin TW, Krall JM, Russell KJ, Peters LJ, Thomas FJ, Hendrickson FR, Laramore GE: Fast neutron irradiation of locally advanced prostate cancer. Seminars in Oncology 15(4): 359-365, 1988.

4. Russell KJ, Boileau MS: Current status of prostate-specific antigen in the radiotherapeutic management of prostatic cancer. Seminars in Radiation Oncology 3(3): 154-168, 1993.

5. Stelzer K, Koh W-J, Greer B, Cain J, Tamimi H, Russell K, Figge D: Intraoperative electron beam therapy (IOEBT) as an adjunct to radical salvage for recurrent cancer of the cervix. In: Schildberg FW, Willich N, Kramling H-J (eds). Intraoperative Radiation Therapy: Proceedings of the 4th International Symposium on Intraoperative Radiation Therapy. Essen, Germany: Verlag, 1993: 411-414.

6. Galloway DA, Demers GW, Foster SA, Halbert CL, Russell K: Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes, In: Cold Spring Harbor Symposia on Quantitative Biology, The Molecular Genetics of Cancer, 59:297-306, 1994

7. Lindsley KL, Cho P, Stelzer KJ, Koh W-J, Austin-Seymour M, Russell KJ, Laramore GE, Griffin TW. Fast neutrons in prostatic adenocarcinomas: worldwide clinical experience. Recent Results Cancer Res 150:125 – 36, 1998.

Submitted:

Landis D, Wallner K, Locke J, Ellis W, Russell K, Cavanagh W, and Blasko J: Late urinary morbidity after prostate brachytherapy. Int. J. Radiat. Oncol., Biol., Phys.

McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener M, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE: High-dose immunosuppressive therapy for severe systemic sclerosis – intial outcomes. Blood.

 

In Preparation:

Russell KJ, Pajak, TJ, Burneson M, Maor MH, Taylor ME, Davis LW, Laramore GE: Fast neutron radiotherapy versus photon radiotherapy for locally advanced adenocarcinoma of the prostate: Final report on a randomized clinical trial of the neutron therapy collaborative working group. Int. J. Radiat. Oncol., Biol., Phys., (Requested Manuscript).
Miller EA, Ellis WJ, and Russell KJ: Redefining prostate fossa radiation fields for adjacent or salvage radiotherapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.

Book Chapters:

2. Russell KJ, Higano CS, Boileau MA, Russell AH, Collins C, Koh W-J, Chapman WH, Griffin TW: Combined 5-fluorouracil and irradiation for the treatment of invasive bladder cancer, In: M Rotman and CJ Rosenthal (eds). Medical Radiology – Diagnostic Imaging and Radiation Oncology. Concomitant Continuous Infusion Chemotherapy and Radiation. Heidelberg: Springer-Verlag; 1991: 175-180.

4. Russell KJ, Blasko JC: Recent advances in interstitial brachytherapy for localized prostate cancer, In: PH Lange (ed). Problems in Urology: Therapeutic Strategies in Prostate Cancer. New York: Lippincott, 1993: 260-279.

5 Russell KJ: Current research directions in the radiation therapy of localized prostate cancer, In: NA Dawson, NJ Vogelzang (Co-eds). Prostate Cancer. Series: Current Clinical Oncology. New York: Wiley-Liss: 1994.

 

Books; Videos; Software:

Colon Cancer – Patient Education Video. Time-Life, Inc. C. Everett Koop, MD, Narrator and Series Editor.
Consultant: Prostate Cancer. Patient Education Video. Time-Life Cancer Video, Patient Education Media, Inc.

Abstracts / Presentations:

1. Russell KJ, Donaldson SS, Cox RS, Kaplan HS: Childhood Hodgkin’s disease: Patterns of relapse. American Society of Therapeutic Radiologists, Los Angeles, California, 10/83.

2. Russell KJ, Elford HL, Bump EA, Rice GC, Brown JM: Radiation sensitization by benzo hydroxamic inhibitors of ribonucleotide reductase. Radiation Research Society, Los Angeles, California, 5/85.

3. Russell KJ, Rice GC, Brown JM: In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine. Radiation Research Society, Los Angeles, California, 5/85.

4. Krieger JN, Laramore GE, Russell KJ, Griffin TW: Fast neutron radiotherapy for locally advanced prostate cancer: Update of a past trial and future treatment directions. American Urological Association, Anaheim, California, 1/87.

 

6. Russell KJ, Brown DM, Yu N, Conley F, Luck E: Intratumoral diffusion-limited cytotoxic chemotherapy for localized potentiation of radiation: Pre-clinical pharmacokinetic and biodistribution studies and in vivo trials of efficacy. American Society for Therapeutic Radiology and Oncology, Boston, Massachusetts, 10/87.

7. Boileau MA, Russell KJ, Ireton R, Collins C, Higano C: Bladder preservation: Neoadjuvant 5-fluorouracil and irradiation as primary management of invasive bladder cancer. Northwest Urological Society, Portland, Oregon, 12/5/87. Award – Outstanding Scientific Presentation

8. Boileau MA, Russell KJ, Ireton RC, Collins C, Higano T: Bladder Preservation: Neoadjuvant 5-fluorouracil and irradiation as primary management of invasive bladder cancer. American Urologic Association Meeting, Boston, Massachusetts, 6/4/88.

9. Collins C, Russell KJ, Boileau MA, Higano C: A pilot study of neo-adjuvant 5 fluorouracil (5-FU) and irradiation (XRT) in the treatment of bladder cancer. American Society of Clinical Oncology Meeting, New Orleans, Louisiana, 5/20/88.

10*. Evolving Combined Modality Strategies for Invasive Bladder Cancer. Visiting Professor, University of Michigan Hospital, Ann Arbor, Michigan, 9/13/88.

11. Griffin B, Wells G, Russell K, and Shuman W: Radiotherapy for primary spinal cord tumors. American Society for Therapeutic Radiology and Oncology, New Orleans, Louisiana, 10/12/88.

12. Griffin BR, Livingston RB, Stewart GR, Higano C, Russell KJ, Griffin TW, Laramore GE: Prophylactic cranial irradiation for limited non-small cell lung cancer. The American Radium Society, Seattle, Washington, 4/16/88.

13. Koh W-J, Russell KJ, Russell AH, Markette K, Tong DY: Combined external beam and intracavitary irradiation for transitional cell carcinoma of the bladder. The American Radium Society, Seattle, Washington, 4/16/88.

14. Russell KJ, Ireton RC, Griffin BR, Boileau MA, Higano C, Collins C, Koh W-J, Laramore GE, Griffin TW: Neoadjuvant 5-fluorouracil and irradiation as non-surgical management of invasive transitional cell carcinoma of the urinary bladder. The American Radium Society, Seattle, Washington, 4/16/88.

15. Russell KJ, Livesey JC, Eary JF, Rasey JS, Krohn KA, Vera DR, Stadalnik RC: Technetium 99M galactosyl neoglycoalbumin (TcNGA) measurement of functional hepatic mass following hepatic irradiation. American Society for Therapeutic Radiology and Oncology, New Orleans, Louisiana, 10/12/88.

16*. The Role of Radiation Therapy in the Treatment of Invasive Bladder Cancer: Past, Present, and Future. Southwest Oncology Group Meeting, Seattle, Washington, 10/24/88.

17*. After Radical Prostatectomy, What Should be Done About Disease Extending Through the Capsule? University of Chicago 8th Annual Frontiers in Medicine Course: Controversies in the Management of Prostate Cancer, Chicago, Illinois, 4/5/89.

18*. Combined 5-Fluorouracil and Irradiation for the Treatment of Invasive Bladder Cancer. State University of New York-Health Science Center at Brooklyn and The American Cancer Society-New York City Division: Second Conference on Clinical Applications of Concomitant Infusion Chemotherapy and Radiation, New York, New York, 4/7/89.

19. Eary JF, Russell KJ, Livesey JC, Rasey JS, Krohn KA, Durack L, Wiens L, Vera DR, Stadalnik RC: Measurement of functional hepatic irradiation with Tc-99m galactosyl neoglycoalbumin (TcNGA). Society of Nuclear Medicine, St. Louis, Missouri, 6/89.

20*. Evolving Concepts in the Management of Prostate Cancer: Past, Present, and Neutrons. Visiting Professor, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, 4/6/89.

21. Koh W, Rasey J, Grierson J, Graham M, Modell H, Russell K, Griffin T, Krohn K: Imaging tumor hypoxia using positron emission tomography imaging of [F-18] Fluoromisonidazole: A report of work during the ASTRO research year. American Society for Therapeutic Radiology and Oncology, San Francisco, California, 10/89.

 

23. Russell KJ, Koh W-J, Griffin BR, Austin-Seymour MM, Laramore GE, Griffin TW: Early and late neurologic complications of radiation therapy in the primary management of adenocarcinoma of the prostate. American Radium Society, St. Thomas, U.S. Virgin Islands, 4/17/89.

24. Stewart GR, Koh W-J, Russell KJ, Russell AH, and Cain JM: Radical re-irradiation for recurrent or second primary carcinomas of the female reproductive tract. American Radium Society, St. Thomas, U.S. Virgin Island, 4/16/89.

25*. What are the Treatment Results for Stage B2 Prostate Cancer? University of Chicago 8th Annual Frontiers in Medicine Course: Controversies in the Management of Prostate Cancer, Chicago, Illinois, 4/5/89.

26*. What is the Optimal Radiotherapeutic Management of Stage C Disease? University of Chicago 8th Annual Frontiers in Medicine Course: Controversies in the Management of Prostate Cancer, Chicago, Illinois, 4/5/89.

27*. What is the Optimal Treatment for Stage A1 Prostate Cancer? University of Chicago 8th Annual Frontiers in Medicine Course: Controversies in the Management of Prostate Cancer, Chicago Illinois, 4/5/89.

28. Wiens LW, Russell KJ, Livesey JC, Eary JF, Krohn KA: Functional hepatic imaging following hepatic irradiation in dogs. Radiation Research Society, Seattle, Washington, 3/21/89.

29*. Conservative Treatment for Bladder Carcinoma. 10th Annual Current Approaches to Radiation Oncology, Biology, Physics. University of California School of Medicine, San Francisco, California, 2/28/90.

30*. Innovations in Radiation Therapy: Particle Therapy. Central Oregon Oncology Conference – Biologic Agents and New Cancer Therapies for the 1990′s, Bend, Oregon, 2/1/90.

31*. Intraoperative Radiation Therapy. Central Oregon Oncology Conference – Biological Agents and New Cancer Therapies for the 1990′s, Bend, Oregon, 2/1/90.

32. Laramore GE, Krall JM, Thomas FJ, Russell KJ, Peters LJ, Hendrickson FR, Davis LW: Fast neutron radiotherapy for locally-advanced prostate cancer: 10-year results of a Radiation Therapy Oncology Group (RTOG) clinical trial. American Radium Society, Scottsdale, Arizona, 4/90.

33*. Radiation Treatment of Bladder Cancer. Providence Medical Center CME Course: Cancer Update 1990, Portland, Oregon, 5/10/90.
34. Russell KJ, Dunatov D, Hafermann MD, Griffeth JT, Polissar L, Pelton JG, Cole SB Taylor EW, Wiens LW, Koh W-J, Austin-Seymour MM, Griffin BR, Russell AH, Laramore GE, Griffin TW: Rapid decline of post-treatment serum prostate specific antigen (PSA) as a predictor for clinical outcomes in patients with adenocarcinoma of the prostate treated with primary external beam irradiation. American Radium Society, Scottsdale, Arizona, 4/90.

35. Russell KJ, Dunatov D, Hafermann MD, Griffeth JT, Polissar L, Pelton JG, Cole SB, Taylor EW, Wiens LW, Koh W-J, Austin-Seymour MM, Griffin BR, Russell AH, Laramore GE, Griffin TW: Rapid decline of post-treatment serum prostate specific antigen (PSA) as a predictor for clinical outcomes in patients with adenocarcinoma of the prostate treated with primary external beam irradiation. Proceedings of the American Society of Clinical Oncology 9:136, 1990.

36. Wallace HJ, Koh W-J, Greer BE, Cain JM, Russell KJ, Russell AH, Tamimi HK, Figge DC. Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Western Association of Gynecologic Oncologists, 20th Annual Meeting, Durango, CO, June 17-20, 1992.

37. Wallace HJ, Koh W-J, Greer BE, Cain JM, Russell KJ, Russell AH, Tamimi HK, Figge DC: Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Western Association of Gynecologic Oncologists, Durango, Colorado, 6/92.

38. Wynne TD, Russell KJ, Anderson K, Taylor E, Tesh D, Tong D, Koh W-J, Collins C, Pelton JW, Griffin TW. The impact of staging laparotomy on relapse rate in clinical stage IA and IIA Hodgkin’s disease: an eighteen-year multi-institutional experience. Proceedings of the 34th Annual ASTRO Meeting. Int. J. Radiat. Oncol. Biol. Phys. 24(S1):123, 1992.

39. Wynne TD, Russell KJ, Anderson K, Taylor E, Tesh D, Tong D, Koh W-J, Collins C, Pelton JW, Griffin TW: The impact of staging laparotomy on relapse rate in clinical stage IA and IIA Hodgkin’s Disease: An eighteen-year multi-institutional experience. 34th Annual Scientific Meeting of the American Society of Therapeutic Radiology and Oncology, San Diego, California, 11/92.

40*. Radiotherapeutic Advances in the treatment of Prostate Cancer. American Cancer Society Course: “Testicular and Prostate Cancer – An Update” Chesterton, Indiana, 5/8/93.

41*. Bladder Cancer Panelist – Do You Agree with the Experts? Panel. American Urological Association Annual Meeting, San Francisco, California, 5/19/94.

42. Galloway D, Demers GW, Foster S, and Russell K: Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes. Cold Springs Harbor Symposium on Quantitative Biology: Molecular Genetics of Cancer, Cold Springs, New York, 6/94.

43. Stelzer KJ, Hibbert K, Koh W-J, Russell KJ, Griffin TW: Association between methylxanthine consumption and a lower incidence of severe chronic radiation toxicity in patients treated for prostate cancer. American Society for Therapeutic Radiology and Oncology, San Francisco, CA, 9/94.

44. Thomas CR, Kimmey MB, Russell KJ, Wood DE, Griffin TW, Austin-Seymour M, et al: Phase II study of neoadjuvant chemoradiation therapy for Stage IIB-III adenocarcinoma of the esophagus and gastroesophageal junction. 80th Scientific Assembly and Annual Meeting, Radiological Society of North America, Chicago, Illinois, 11/94.

45. Thomas CR, Kimmey MB, Russell KJ, Wood DE, Griffin TW, Austin-Seymour M, et al: Phase II study of neoadjuvant chemoradiation therapy for Stage IIB-III adenocarcinoma of the esophagus and gastroesophageal junction. Radiology 192(SS):284, 1994.

46. Novel Strategies Against Resistant Tumors. AACR Symposium, Vic Ling/Dan VanHoff Symposium Directors, Sanibel Island, Florida, 11/95.

47. Russell KJ, Wiens LW, Demers GW, Galloway DA, Groudine M: Abrogation of the G2 checkpoint by methylxanthines results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent A549 human lung cancer cells. American Society for Therapeutic Radiology and Oncology Annual Meeting, Miami Florida, 10/11/95.

48*. Russell, KJ: Fast neutron treatment of prostate cancer. Current Approaches to Radiation Oncology, Biology, Physics, 16th Annual Meeting, University of California School of Medicine, San Francisco California, 3/10/97.

49*. Russell, KJ: Integrating oncologic imaging and treatment planning for prostate cancer. NCI Workshop, “Oncologic Imaging in Treatment Planning 9/ 25-26, 1997.

50*. Russell, KJ: Have we made progress in bladder cancer organ preservation trials? American Society for Therapeutic Radiology and Oncology Annual Meeting, Orlando Florida, 10/97.

51. Schwartz, JL, Rasey, J, Russell, KJ: The repair of radiation-induced potentially lethal damage and p53 dependent G1 arrest are tightly-linked processes. Radiation Research Society, Louisville, Kentucky, 4/25-29, 1998.

52. Miller EA, Ellis WJ, Russell KJ: Redefining radiation fields for adjuvant radiotherapy for prostate cancer. Western Section, American Urological Association Meeting, Hawaii, 10/98.

53. Miller EA, Ellis WJ, Lange P, Russell KJ: Adjuvant radiation therapy for prostate cancer: Preliminary report of outcome. Western Section, American Urological Association Meeting, Hawaii, 10/98.

54. Michalski JM, Roach M, Vijayakumar S, Winter K, Harms WB, Sandler HM, Markoe A. Ritter MA, Russell KJ, Sailer S, Purdy JA, Perez CA, Hanks GE, Cox JD: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. 1998 ASTRO Meeting, Phoenix, Arizona, 10/98.

55*. Russell KJ: Dose escalation in prostate cancer. How much and for whom? American Society for Therapeutic Radiology and Oncology Annual Meeting, Phoenix, Arizona, 12/98.

56*. Russell KJ: Dose escalation, neo-adjuvant hormones, and quality of life outcomes – Evaluating three “Holy Grails” of prostate radiotherapy. American Society of Clinical Oncology Annual Meeting, Atlanta, Georgia 5/16/99.

58. Ellis WJ, Miller EA, Russell KJ: Redefining prostatic fossa radiation fields for adjuvant or salvage radiotherapy of prostate cancer. American Society of Therapeutic Radiology and Oncology Annual Meeting, San Antonio, Texas, 11/99. Int J Radiat Oncol, Biol, Phys, Volume 45, #3 Supplement, p 259.

59. Russell KJ. Pajak TJ, Burnison CM, Maoir MH, Taylor ME, Davis LW, Laramore GE: Fast neutron radiotherapy vs. photon radiotherapy for locally-advanced adenocarcinoma of the prostate: final report on a randomized clinical trial of the Neutron Therapy Collaborative Working Group. American Society of Therapeutic Radiology and Oncology Annual Meeting, San Antonio, Texas, 11/99. Int J Radiat Oncol, Biol, Phys, Volume 45, #3 Supplement, p 168.

60*. Russell KJ: Translational research in Radiation Oncology. Invited participant, NCI Workshop, Bethesda, Maryland, 9/9 – 9/10/99.

61*. Russell KJ: Prostate brachytherapy: Patient selection, dosimetry, and evaluation of implant quality. AUA Refresher Course Instructor, Western Section, American Urological Association Meeting, Monterey, California, 9/27 – 9/28/99.

62*. Russell KJ: Controversies in Prostate Cancer Management with Brachytherapy, Visiting Professor, State University of New York, 11/22/99.

63. Masood N, Russell KJ, Doney KC, Sabath DE, Olerud JE, Sale GE, Fefer A, Thompson JA: Induction of Complete Remission of Advanced Stage Mycosis Fungoids by Allogenic Hematopoietic Stem Cell Transplantation: A Case Report. American Society of Hematology Annual Meeting, 12/3 – 12/7/99, New Orleans, LA. Blood, Volume 94, #10 Supplement 1, Abstract p 4947.

 

Abstracts / Presentations:

(* = Invited):

1.

2. Russell KJ, Laramore GE, Krall JM, Griffin TW: Eight-year results of neutron radiotherapy in the treatment of locally advanced prostate cancer: Results of a Radiation Therapy Oncology Group randomized clinical trial. European Society for Therapeutic Radiology and Oncology, Lisbon, Portugal, 5/28/87.

3. Koh W-J, Austin-Seymour MM, Russell KJ, Griffin BR, Laramore GE, Griffin TW: Current use of electron beam therapy in the United States. International Congress on Physics and Oncological Radiotherapy – High Energy Electrons, Genoa, Italy, 11/90.

4. Koh W-J, Cain J, Greer B, Tamimi H, Figge D, Russell KJ, Laramore GE, Griffin TW: Intraoperative radiation therapy (IORT) for recurrent cancer of the uterine cervix: III International Symposium on Intraoperative Radiation Therapy, Kyoto, Japan, 11/90.

5. Koh W-J, Russell KJ, Cain JM, Greer BE, Tamimi HK, Figge DC, Laramore GE, Griffin TW: Intraoperative electron beam therapy. International Congress on Physics and Oncological Radiotherapy – High Energy Electrons, Genoa, Italy, 11/90.

6. Russell KJ, Dunatov C, Hafermann MD, Griffeth JT, Polissar L, Pelton J, Cole SB, Taylor EW, Weins LW, Koh W-J, Austin-Seymour MM, Griffin BR, Russell AH, Laramore GE, Griffin TW: Rapid decline of post-treatment PSA as a predictor for clinical outcomes in patients with prostate cancer treated with primary irradiation. International Testicular and Prostatic Cancer Conference, Toronto, Canada, 10/90.

7. Russell KJ, Dunatov C, Hafermann MD, Griffeth JT, Polissar L, Pelton J, Cole SB, Taylor EW, Wiens LW, Koh W-J, Austin-Seymour MM, Griffin BR, Russell AH, Laramore GE, Griffin TW: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate with primary radiation therapy. European Society for Therapeutic Radiology and Oncology, Montecatini, Italy, 9/90.

8. Griffin TW, Krall JM, Laramore GE, Burneson M, Maor MH, Russell KJ, Zink S: Fast Neutron Radiotherapy of Locally Advanced Prostate Cancer: Symposium of Locally Advanced Prostate Cancer: Basic Research and Clinical Considerations, Bochum, Germany, 11/91.

9. Koh W-J, Stelzer K, Greer B, Cain J, Tamimi H, Russell K, Figge D, Griffin T. Intraoperative electron beam therapy (IOEBT) as an adjunct to radical salvage for recurrent cancer of the cervix. Fourth International Symposium on Intraoperative Radiation Therapy, Munich, Germany, 9/92.

10. Griffin TW, Krall JM, Laramore GE, Parker RG, Burneson M, Peters LJ, Maor MH, Russell KJ, Davis LW: Neutron vs. photon irradiation for locally advanced prostate cancer: Report of a randomized clinical trial. International Congress of Radiation Oncology, Kyoto Japan, 6/93.

11. Russell KJ: Cellular repair of potentially lethal radiation damage (PLDR) is correlated with deficient G1/S checkpoint function. American Radium Society, Bermuda, 4/94.

12*. Russell KJ: New approaches for a new millennium: prostate brachytherapy. American Radium Society, Monte Carlo, Monaco 5/98.

13*. Russell KJ: Permanent Prostate Seed Brachytherapy – Patient selection parameters. 1st Italian Conference on Transperineal Brachytherapy for Treatment of Tumors of the Prostate. Italian Society of Urology, San Raffaele Hospital, Milan Italy, 11/27 – 11/28/98.

14*. Russell KJ: Permanent prostate seed brachytherapy – Post implant dosimetry, quality assurance, and symptomatic support. 1st Italian Conference on Transperineal Brachytherapy for Treatment of Tumors of the Prostate. Italian Society of Urology, San Raffael Hospital, Milan Italy, 11/27 – 11/28/98.

15*. Russell KJ: Permanent prostate seed brachytherapy – long-term treatment outcomes. 1st Italian Conference on Transperineal Brachytherapy for Treatment of Tumors of the Prostate. Italian Society of Urology, San Raffaele Hospital, Milan Italy, 11/27 – 11/28/98.

16*. Russell KJ: Brachytherapy for prostate cancer – planning, execution, and evaluation of results. University of Dresden course, “Urological days in Dresden”, Dresden Germany 9/3-9/4/99.

17*. Russell KJ: Permanent prostate seed brachytherapy – techniques, outcomes, and future directions: Bassano Urological Meeting, “Benign Prostatic Hypertrophy and Prostatic Carcinoma”, Bassano del Grappa, Italy, 11/17-11/18/99.

18*. Russell KJ: Performed Live – Prostate Brachytherapy procedure with live video teleconference. San Raphael Hospital, Milan, Italy, 11/19/99.

19*. Russell KJ: Brachytherapy in the treatment of localized prostate cancer. International Congress, “Carcinoma of the Prostate”. Genoa, Italy, 3/26-3/28/00.

20*. Russell KJ: Current Issues in Genitourinary Cancer. Session Moderator, American Radium Society, London, England. 4/1-4/5/00.

21*. Russell KJ: Techniques and results of LDR permanent seed brachytherapy for prostate cancer. Fifth International Symposium on Special Aspects of Radiotherapy – “Controversies in Uro-oncology”. Berlin, Germany, 5/12 – 5/14/2000.